The Greenrose Holding Company Inc. (GNRSU) is trading at USD 0.00 (recorded USD 0.000001) on the PNK exchange in the United States during market hours on 02 Mar 2026. GNRSU stock is a top loser today, down about -99.99% on the session with volume 145.00 shares. Immediate liquidity and balance sheet metrics are driving the drop, making valuation and short-term recovery prospects the key focus for investors and analysts.

Price action and market context for GNRSU stock

GNRSU stock fell from a previous close of USD 0.15 to an intraday print near USD 0.00 on 02 Mar 2026. The one-day change shows a decline of -99.99% and trading volume was 145.00 shares. This move places GNRSU among the top losers in the small-cap PNK health-care group and highlights severe liquidity stress in the quote.

Financial snapshot and clearest ratios tied to GNRSU performance

The Greenrose Holding Company Inc. reports EPS 3.10 and an effectively negligible P/E due to the current quoted price (reported P/E ~ 0.00). Book value per share is 4.30, cash per share 0.56, and shares outstanding are 12,853,627.00. Current ratio is 0.21, and debt to equity stands near 1.57, showing short-term coverage and leverage concerns that connect directly to the price collapse.

Operational and sector drivers behind the GNRSU stock move

Greenrose operates in the Healthcare sector and Drug Manufacturers – Specialty & Generic industry, focused on cannabis cultivation and processing. Sector-level regulatory uncertainty and pricing pressure on cannabis products can reduce margins and inventory turns; GNRSU shows days of inventory on hand 439.24, pointing to inventory build and slower sales conversion. These operational signals likely amplified the selloff.

Meyka AI rates GNRSU with a score out of 100 and technical view

Meyka AI rates GNRSU with a score of 67.12 / 100 and assigns a Grade B, Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. The grade is informational only and not investment advice.

Valuation, liquidity and risks for GNRSU stock

Price-to-book and price-to-sales ratios are effectively near zero at the quoted price, understating intrinsic metrics because market price collapsed. Market cap is recorded at USD 13.00, while enterprise value metrics in filings show large discrepancies, signaling potential data or quote issues. Major risks include thin liquidity, possible quote anomalies, regulatory exposure, and working capital shortfalls (working capital reported at -103,434,000.00).

Catalysts, timeframe and trading strategy for GNRSU stock

Near-term catalysts would include audited financial statements, clarifying disclosure from management, or a reverse split or corporate action to restore tradability. Given current volume and spread, short-term trading is high risk; longer-term recovery depends on operational turnarounds and sector regulatory clarity. Traders should size positions small and prefer limit orders if they elect to trade GNRSU.

Final Thoughts

Key takeaways for GNRSU stock: the quote collapse to USD 0.00 on 02 Mar 2026 reflects extreme illiquidity and balance-sheet scrutiny rather than a routine market move. Cash per share is 0.56 and book value per share is 4.30, yet market price and market cap (USD 13.00) imply a disconnect between reported fundamentals and market pricing. Meyka AI’s forecast model projects a 12-month scenario price target of USD 0.05, which implies an upside of roughly 4,999,900.00% from the current recorded price (USD 0.000001). Forecasts are model-based projections and not guarantees. Investors should treat GNRSU as speculative, confirm quotes with primary sources, and monitor filings, management updates, and sector policy changes before allocating capital. For real-time monitoring and deeper metrics, see the company site and official quote pages linked below.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.